Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Desallais, Lucille ^a   Avouac, Jérôme ^b,c   Fréchet, Maxime ^c   Elhai, Muriel ^c   Ratsimandresy, Rojo ^d   Montes, Matthieu ^a   Mouhsine, Hadley ^a   Do, Hervé ^d   Zagury, Jean François ^a   Allanore, Yannick ^b,c  

^a University of Paris Cité   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d Peptinov Cochin Santé Business Accelerator Pépinière Cochin Santé Cochin Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; BLEOMYCIN; HYDROXYPROLINE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MR 16 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MONOCLONAL ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DISEASE MODEL; FIBROSIS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; SKIN DISEASES;

ADULT; AGED; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; BLEOMYCIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN DISEASES;

EID: 84904519840     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4672     Document Type: Article

References (33)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
3. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis: their role in early and late disease. Pathobiology 1993, 61:239-246.
4. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72.
5. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O, Puddu P, Paganelli R, Russo G. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546.
6. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999, 112:456-462.
7. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
8. Avouac J, Fürnrohr BG, Tomcik M, Palumbo K, Zerr P, Horn A, Dees C, Akhmetshina A, Beyer C, Distler O, Schett G, Allanore Y, Distler JH. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011, 63:800-809.
9. Avouac J, Elhai M, Tomcik M, Ruiz B, Friese M, Piedavent M, Colonna M, Bernhardt G, Kahan A, Chiocchia G, Distler JH, Allanore Y. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013, 72:1089-1098.
10. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999, 38:612-617.
11. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013, 40:435-446.
12. Jurisic Z, Martinovic-Kaliterna D, Marasovic-Krstulovic D, Perkovic D, Tandara L, Salamunic I, Carevic V. Relationship between interleukin-6 and cardiac involvement in systemic sclerosis. Rheumatology (Oxford) 2013, 52:1298-1302.
13. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, Katayama I. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012, 180:165-176.
14. Le Huu D, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 2012, 132:2752-2761.
15. Ratsimandresy RA, Duvallet E, Assier E, Semerano L, Delavallee L, Bessis N, Zagury JF, Boissier MC. Active immunization against IL-23p19 improves experimental arthritis. Vaccine 2011, 29:9329-9336.
16. Bertin-Maghit SM, Capini CJ, Bessis N, Chomilier J, Muller S, Abbas A, Autin L, Spadoni JL, Rappaport J, Therwath A, Boissier MC, Zagury JF. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 2005, 23:4228-4235.
17. Capini CJ, Bertin-Maghit SM, Bessis N, Haumont PM, Bernier EM, Muel EG, Laborie MA, Autin L, Paturance S, Chomilier J, Boissier MC, Briand JP, Muller S, Cavaillon JM, Therwath A, Zagury JF. Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 2004, 22:3144-3153.
18. Delavallee L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC. Vaccination with cytokines in autoimmune diseases. Ann Med 2008, 40:343-351.
19. Wipff J, Allanore Y, Boileau C. Interactions between fibrillin-1 and tgf-beta: consequences and human pathology. Med Sci (Paris) 2009, 25:161-167.
20. Avouac J, Clemessy M, Distler JH, Gasc JM, Ruiz B, Vacher-Lavenu MC, Wipff J, Kahan A, Boileau C, Corvol P, Allanore Y. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. Rheumatology (Oxford) 2011, 50:1494-1504.
21. Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, Maurer B, Akhmetshina A, Beyer C, Sadowski A, Schneider H, Shiozawa S, Distler O, Schett G, Allanore Y, Distler JH. Inhibition of activator protein 1 signaling abrogates transforming growth factor beta-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012, 64:1642-1652.
22. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976, 82:493-512.
23. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, Takeda Y, Ohsugi Y. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998, 41:2117-2121.
24. Woessner JF, Boucek RJ. Connective tissue development in subcutaneously implanted polyvinyl sponge. I. Biochemical changes during development. Arch Biochem Biophys 1961, 93:85-94.
25. Tutorials and examples of the ImageJ software: Quantifying stained liver tissue. [http://imagej.nih.gov/ij/docs/examples/stained-sections/index.html].
26. Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, Boileau C, Allanore Y. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford) 2008, 47:972-975.
27. Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T, Mihara M. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008, 8:1595-1601.
28. Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010, 62:2831-2844.
29. Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 2012, 71:1235-1242.
30. Wallace VA, Kondo S, Kono T, Xing Z, Timms E, Furlonger C, Keystone E, Gauldie J, Sauder DN, Mak TW. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994, 24:1463-1466.
31. Phelps RG, Daian C, Shibata S, Fleischmajer R, Bona CA. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 1993, 6:701-718.
32. Dodig TD, Mack KT, Cassarino DF, Clark SH. Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 2001, 44:723-727.
33. Ratsimandresy RA, Rappaport J, Zagury JF. Anti-cytokine therapeutics: history and update. Curr Pharm Des 2009, 15:1998-2025.